Fig. 4: Changes in phospholipid and sphingolipid classes in response to Enza treatment. | Prostate Cancer and Prostatic Diseases

Fig. 4: Changes in phospholipid and sphingolipid classes in response to Enza treatment.

From: Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy

Fig. 4: Changes in phospholipid and sphingolipid classes in response to Enza treatment.

A Paired comparisons showing the absolute levels of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI) before and after enza treatment. B Stacked bar plot showing the relative distribution of phospholipid subclasses as a percentage of total phospholipids. C Paired comparisons of ceramide (Cer) and sphingomyelin (SM) levels pre- and post-treatment. D Stacked bar plot showing the relative composition of sphingolipid subclasses as a percentage of total sphingolipids. Asterisks indicate statistically significant differences (p < 0.05).

Back to article page